Catalog No.
Product Name
Application
Product Information
Citations
-
Anti-Inflammatory Agent
Ramifenazone, a pyrazole derivative, functions as a non-steroidal anti-inflammatory agent (NSAID) primarily through the inhibition of cyclooxygenase enzymes, leading to reduced prostaglandin synthesis. It exhibits significant analgesic, antipyretic, anti-inflammatory, and antimicrobial activities, making it valuable for various research applications in inflammation and pain management studies. Its multifaceted properties support its use in investigating therapeutic approaches for inflammatory diseases and related conditions. -
Anti-inflammatory Agent
2′-Hydroxygenistein is an anti-inflammatory compound derived from the natural sources Crotalaria pallida and C. assamica. It demonstrates concentration-dependent inhibitory effects on the release of β-glucuronidase and lysozyme from rat neutrophils, exhibiting IC50 values of 5.9 ± 1.4 μM and 9.7 ± 3.5 μM, respectively. This compound serves as a valuable tool for research applications in inflammation studies and the modulation of immune responses. -
COX-1/2 Inhibitor
2-(p-Tolyl)propanoic acid is a selective inhibitor of COX-1 and COX-2 enzymes, displaying IC50 values of 38.23 μM and 64.30 μM, respectively. This compound exhibits antimicrobial properties and is relevant for research on bacterial pathogens such as Escherichia coli, Enterococcus faecalis, Listeria monocytogenes, and Staphylococcus aureus. Its mechanism of action positions it as a valuable tool for investigating inflammatory processes and antimicrobial resistance in various biological studies. -
Dye/P2×7R Antagonist
Brilliant Blue G-250 is a dye that functions as a P2×7 receptor (P2×7R) antagonist. It exhibits selective inhibition of P2×7R, leading to the inactivation of the NLRP3 inflammasome, which is crucial in inflammatory processes. This compound is widely utilized for protein visualization in SDS-PAGE, providing a straightforward staining method alongside high quantitation capabilities in the Bradford protein assay, where protein concentrations are assessed by measuring absorbance at 595 nm. -
Anti-inflammatory Agent
Selenomethylene blue is an antioxidant with potent anti-inflammatory properties. It has been shown to effectively inhibit inflammatory paw edema in rodent models, making it a valuable tool for studying inflammation-related pathways. Its applications extend to research in chronic inflammatory conditions and potential therapeutic interventions. -
Antiviral Agent
Brilliant Black BN is an azo dye with a notable application as an antiviral agent. It effectively inhibits the interaction between enterovirus 71 (EV71) and its uncoating factor, cyclophilin A, demonstrating significant potential in the treatment of viral infections. This compound serves as a valuable tool for research focused on antiviral mechanisms and infectious disease studies. -
WNT7A Inhibitor/Photosensitizer
WNT7A-IN-1 sodium is a selective inhibitor of WNT7A that disrupts the interaction between WNT7A and its receptor FZD5, leading to enhanced expression of MHC-I. This reagent is known to significantly increase levels of MHC-I and phosphorylated p65 while decreasing active β-catenin expression. Additionally, WNT7A-IN-1 sodium acts as a photosensitizer in the green spectral region, making it suitable for applications in photodynamic therapy and immunological studies. -
STING Agonist
STING agonist-18 is a potent agonist of the stimulator of interferon genes (STING) pathway, known for its ability to activate immune responses. This compound is particularly useful in the synthesis of antibody-drug conjugates (ADCs), such as Trastuzumab conjugates, facilitating targeted therapeutic approaches. Its application in cancer immunotherapy and related research enhances the understanding of STING pathway modulation in tumor microenvironments. -
Intermediate Product
TAM558 Intermediate-5 is a pivotal intermediate in the synthesis of TAM558, which serves as the payload molecule for the formation of OMTX705. OMTX705 is a humanized antibody targeting fibroblast activation protein (FAP), facilitating cytolysis via binding to TAM470. This intermediate is essential for research into anti-tumor therapies and the development of novel cancer treatments targeting the tumor microenvironment. -
Intermediate Product
TAM558 intermediate-2 is a critical intermediate in the synthesis of TAM558, a payload molecule used in the preparation of OMTX705. OMTX705 is a humanized antibody targeting fibroblast activation protein (FAP), which exhibits significant anti-tumor activity by binding to the cytolysin TAM470. This intermediate plays a vital role in facilitating the development of innovative therapeutic agents for cancer treatment. -
COX-2/Carbonic Anhydrase Inhibitor
Polmacoxib is a novel, orally active nonsteroidal anti-inflammatory drug (NSAID) that acts as a dual inhibitor of cyclooxygenase-2 (COX-2) and carbonic anhydrase, with an IC50 value of approximately 0.1 μg/ml for COX-2. It exhibits significant biological activity by inhibiting the growth of colorectal adenomas and tumors in mouse models, making it a promising tool for cancer research. Polmacoxib is valuable for studying the roles of COX-2 and carbonic anhydrase in cancer biology and inflammation. -
COX-2 Inhibitor
COX-2-IN-30 is a benzenesulfonamide derivative that functions as a potent selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 of 49 nM and also inhibits 5-lipoxygenase (5-LOX) with an IC50 of 2.4 μM. Additionally, it affects human carbonic anhydrase isoforms IX and XII, displaying nanomolar Ki values. This compound demonstrates significant analgesic and anti-inflammatory properties while maintaining a favorable gastrointestinal safety profile, making it useful for research in inflammation, pain relief, and related gastrointestinal studies. -
OMTX705 Payload Molecule
TAM558 is a payload molecule utilized in the synthesis of OMTX705, a humanized anti-fibroblast-activating protein (FAP) antibody conjugated to the cytolysin TAM470. This conjugation enhances the antitumor activity of OMTX705, making it a valuable tool in cancer research. The combination of TAM558 with targeted antibodies facilitates the development of innovative therapeutic strategies against tumor-associated fibroblasts. -
BRD4/FKBP Binding Agent
HLDA-221 is a non-covalent regulated induced proximity targeting agent (RIPTAC) that selectively binds to BRD4-BD1 upon pre-incubation with FKBP. This compound facilitates protein-protein interactions, making it a valuable tool for studying cellular signaling pathways and gene regulation. HLDA-221 has potential applications in cancer research, particularly in understanding the role of BRD4 in tumorigenesis and therapeutic targeting. -
Transcriptional Chemical Inducers of Proximity
JWZ-7-7-Neg1 is a transcriptional chemical inducer of proximity (TCIP) designed with negative chemical control. This compound selectively reduces the binding affinity to BRD4 and BCL6, thereby exhibiting decreased cytotoxicity in diffuse large B-cell lymphoma (DLBCL) cells compared to its counterpart, JWZ-7-7. JWZ-7-7-Neg1 serves as a valuable tool in cancer research, particularly for studies focusing on transcriptional regulation and targeted therapies. -
p300/CBP Inhibitor
KB528 is a selective inhibitor of the histone acetyltransferases p300 and CBP, demonstrating low nM IC50 values against these targets while sparing other members of the KAT family. This compound modulates the IRF4 transcriptional network, leading to decreased expression of key oncogenes such as IRF4, MYC, CAV2, and IGLL5, as well as reduced levels of IKZF3 protein. KB528 has been shown to effectively induce apoptosis in multiple myeloma cells, making it a valuable tool for research in multiple myeloma and related oncological studies. -
CD206 Targeted Fluorescent Dye
MR2-cy5 is a fluorescent dye specifically designed to target CD206, a receptor expressed on macrophages. This reagent enables precise tracking of CD206+ macrophages in various biological samples, facilitating studies in immunology and cellular biology. MR2-cy5 is ideal for applications such as flow cytometry and imaging, contributing to the understanding of macrophage function and behavior in health and disease. -
Inflammatory Pathway Inhibitor, Oxidative Stress Inhibitor, Cancer Pathway Inhibitor
Matairesinol is an orally active bioactive compound that functions as an inflammatory pathway, oxidative stress, and cancer pathway inhibitor. It effectively inhibits the phosphorylation of MAPK, JNK, and NF-κB, while downregulating RANKL-induced NFATc1 expression and activity, and suppressing the activation of the PI3K/AKT/FOXO1 pathway. Matairesinol is applicable in research on sepsis-mediated brain injury, osteoporosis, heart failure, atopic dermatitis, and various cancer models. -
Anti-Inflammatory Agent
Isodorsmanin A is an anti-inflammatory agent that effectively suppresses the production of inflammatory mediators and pro-inflammatory cytokines. This compound inhibits the phosphorylation of c-Jun N-terminal kinase (JNK) and mitogen-activated protein kinase (MAPK), contributing to its anti-inflammatory effects. Isodorsmanin A is useful in research applications focused on inflammation-related disorders and the investigation of signaling pathways involved in inflammatory responses. -
Antiinflammatory Agent
n-Butyl α-D-fructofuranoside is an anti-inflammatory agent that enhances Nrf2 activity through the activation of JNK pathways. This compound, derived from the root barks of Ulmus davidiana var. japonica, exhibits significant anti-inflammatory properties, making it a valuable tool for studying inflammation and oxidative stress in various biological systems. Its potential applications include the investigation of cellular responses to inflammation and the modulation of antioxidant pathways. -
RAS/RAS-RAF Inhibitor
RAS/RAS-RAF-IN-1 is a potent inhibitor targeting the RAS and RAS-RAF signaling pathways. With a dissociation constant (KD) in the range of 5.0 μM to 15 μM for cyclophilin A (CYPA), this compound demonstrates significant binding affinity. RAS/RAS-RAF-IN-1 exhibits notable antitumor activity, making it a valuable tool for cancer research and therapeutic development. -
Anti-Inflammatory Agent
Rhamnocitrin is an anti-inflammatory and antioxidant agent that targets the STIM-1, NFATc3, and MAPK pathways. It effectively scavenges free radicals and exhibits a specific inhibitory effect on oxidative stress and inflammatory responses in vascular endothelial cells and neurons. Through upregulation of miR-185, Rhamnocitrin inhibits STIM-1-mediated store-operated calcium entry, which prevents NFATc3 translocation to the nucleus and reduces the expression of downstream inflammatory factors. Additionally, it induces heme oxygenase HO-1 expression and modulates the ERK/p38 MAPK pathway, mitigating the production of pro-inflammatory cytokines and adhesion molecules. Rhamnocitrin is suitable for research focused on endothelial-related inflammatory diseases and neuroprotection. -
Anti-Inflammatory Agent
Andrograpanin is a bioactive compound derived from Andrographis paniculata, acting primarily as an anti-inflammatory agent. This molecule demonstrates significant anti-inflammatory and anti-infectious properties, making it a valuable tool for research in inflammatory diseases and infections. Its mechanism of action enables the modulation of inflammatory pathways, providing insight for therapeutic development in related conditions. -
Anti-inflammatory/Anti-fibrotic Agent
GDC-3280 is an orally active anti-inflammatory and anti-fibrotic agent that operates primarily through the inhibition of the ASK1-p38 MAPK pathway. It effectively mitigates the inflammatory and fibrotic responses associated with silicosis and influences macrophage polarization. GDC-3280 is a valuable tool for research aimed at understanding and developing therapeutic strategies for inflammatory and fibrotic diseases. -
STING Agonist
2',3'-cGAMP-C2-PPA is a cyclic dinucleotide that acts as a STING (Stimulator of Interferon Genes) agonist. It modulates immune responses by stimulating the production of interferons and other cytokines, making it a valuable tool in cancer immunotherapy research. This compound is particularly useful for studying immune responses in tumor microenvironments and exploring therapeutic strategies for cancer treatment. -
RDC-related Molecule
NOTA-NHS ester is a chelating agent that allows for the creation of radiolabeled compounds, specifically through coupling with T140 to form NOTA-T140. This compound can then be radiolabeled with Al[18F], enabling visualization of tumor uptake that correlates with CXCR4 expression levels. Al[18F]NOTA-T140 is particularly valuable for PET imaging studies of tumors. Additionally, NOTA-NHS ester serves as a versatile tool for fluorescent labeling in various biological applications. -
CXCR4 Targeting Peptide
Pentixafor is a synthetic peptide that targets the CXCR4 receptor, playing a critical role in various cellular processes, including cell migration and signaling. This compound can be labeled with 68Gallium (68Ga), enabling its application in positron emission tomography (PET) imaging for assessing CXCR4 expression in vivo. Additionally, Pentixafor serves as a vital component in the development of Radionuclide-Drug Conjugates (RDCs) for targeted cancer therapies. -
FAP-Targeting Peptide
3BP-3940 is a highly potent and selective peptide inhibitor targeting fibroblast activation protein (FAP) in cancer-associated fibroblasts (CAFs) within the tumor microenvironment. This reagent exhibits significant potential for tumor imaging when labeled with radionuclides such as Ga-68 and for targeted anticancer therapies using Lu-177. 3BP-3940 selectively accumulates in tumor lesions, making it valuable for the diagnosis and treatment of various solid tumors and conditions related to CAFs. -
FAP Inhibitor
FAPI-mFS is an irreversible inhibitor of fibroblast activation protein (FAP), which targets FAP's enzymatic activity to enhance cancer cell uptake and retention through covalent binding. This compound is particularly useful for cancer imaging and therapy when labeled with radioisotopes such as 68Ga or 177Lu. Additionally, FAPI-mFS serves as a valuable tool in the synthesis and research of radionuclide-drug conjugates (RDCs), facilitating advancements in targeted cancer treatments. -
FAP Inhibitor
NOTA-FAPI is a fibroblast activation protein (FAP) inhibitor designed for targeted tumor imaging. This compound effectively binds to FAP, facilitating the visualization of tumors with high detection efficacy. NOTA-FAPI demonstrates superior imaging quality, making it a valuable tool for cancer research and diagnostic applications. -
RDC Peptide
FAP targeting peptide for FXX489 is a polypeptide that specifically targets fibroblast activation protein (FAP). This ligand plays a crucial role in the development of therapeutic agents aimed at modulating FAP-related pathways. It is particularly applicable in cancer research, where FAP is associated with tumor stroma and cancer progression, facilitating targeted delivery of therapeutic compounds. -
Endoradiotherapeutic vector
Anditixafortide is a CXCR4-targeting peptide derivative that functions as an endoradiotherapeutic vector. This reagent is primarily utilized in the synthesis and research of Radionuclide-Drug Conjugates (RDCs), leveraging its ability to selectively target CXCR4-expressing cells. Its application is significant in the field of targeted cancer therapies, facilitating precise delivery of therapeutic radionuclides to tumor sites. -
FAP Targeted Agent
DOTAGA.Glu.(FAPi)2 is a targeted agent that functions as a homodimer specific to fibroblast activation protein (FAP). This compound, which features a central glutamic acid linker connecting FAPi to a chelator, is suitable for radiolabeling with gallium-68, lutetium-177, or terbium-161, making it valuable for PET imaging studies in cancers expressing FAP. Its primary research applications include investigations related to prostate adenocarcinoma and recurrent glioblastoma multiforme, facilitating enhanced imaging and assessment of these malignancies. -
Liposome
DOTA Conjugated JM#21 derivative 7 is a CXCR4-targeting peptide conjugated with DOTA, designed for the synthesis of radioligands. When radiolabeled as 177Lu-DOTA, it demonstrates superior targeting of CXCR4-expressing tumors while exhibiting minimal uptake in non-targeted organs, except for the kidneys. This compound is ideal for research applications involving Radionuclide-Drug Conjugates (RDCs), facilitating advancements in targeted radiotherapy. -
Peptide-PEG2 Conjugate of Unlabeled FXX489
FAP targeting peptide-PEG2 conjugate is a peptide-PEG2 linker conjugate of Unlabeled FXX489, a ligand specifically targeting fibroblast activation protein (FAP). This conjugate facilitates targeted delivery and enhances bioavailability in therapeutic applications. It is primarily employed in research focusing on FAP-related diseases, offering valuable insights into cancer progression and tissue remodeling. -
anti-CD22-Calecheamicin Conjugate
Inotuzumab ozogamicin is an antibody-drug conjugate targeting CD22, composed of a humanized anti-CD22 antibody linked to the cytotoxic agent Calicheamicin. This compound exhibits potent efficacy against CD22-positive B-cell non-Hodgkin’s lymphoma and is being investigated for its potential in treating acute lymphoblastic leukemia. Researchers can utilize Inotuzumab ozogamicin to explore therapeutic strategies for CD22-expressing malignancies. -
Anti-inflammatory Agent
3,5,6,7,8,3',4'-Heptemthoxyflavone is a flavonoid with potent anti-inflammatory properties, functioning as a CREB activator. This compound exhibits anti-tumor and neuroprotective activities by inhibiting collagenase activity and enhancing type I procollagen synthesis in human dermal fibroblast neoblast (HDFn) cells. Additionally, it promotes the expression of brain-derived neurotrophic factor (BDNF) via the cAMP/ERK/CREB signaling pathway and decreases phosphodiesterase activity in C6 glioma cells, making it a valuable tool for research in inflammation and neurobiology. -
Autotaxin Inhibitor
MHC02181 is a potent inhibitor of Autotaxin (ATX), demonstrating an IC50 value of 9.41 μM. By inhibiting ATX, it plays a critical role in modulating lysophosphatidic acid (LPA) production, which is involved in various physiological and pathological processes. This reagent is valuable for research applications focused on cancer progression, fibrosis, and other ATX-mediated diseases. -
Autotaxin Inhibitor
MHC00188 is an allosteric inhibitor of Autotaxin (ATX) with an IC50 of 2.53 μM. This compound modulates ATX activity, which plays a critical role in the production of lysophosphatidic acid (LPA), a signaling lipid involved in various physiological processes. MHC00188 is useful for research into cancer biology, inflammation, and other conditions related to aberrant LPA signaling. -
COX Inhibitor
Aspirin DL-lysine is a lysine-conjugated derivative of aspirin that functions primarily as a cyclooxygenase (COX) inhibitor. This compound effectively inhibits the synthesis of thromboxane A2 (TXA2) in platelets, leading to a reduction in platelet activation and aggregation. Aspirin DL-lysine is valuable for research applications focused on thrombin generation, particularly in clinical studies involving unstable angina pectoris. -
PI3K/Akt Inhibitor, MAPK Inhibitor, NF-κB Inhibitor, Nrf2/ARE Activator
JRN73958 is a potent inhibitor of the PI3K/Akt, MAPK, and NF-κB signaling pathways. This compound effectively reduces LPS/IFNγ-induced activation of these pathways, making it a valuable tool for investigating their roles in cancer biology, particularly in leukemia research. Additionally, JRN73958 acts as an Nrf2/ARE activator, further expanding its utility in studies related to oxidative stress and cell survival mechanisms. -
Anti-Inflammatory Agent
Anti-inflammatory agent 33 is a potent inhibitor of the p38α MAPK pathway. It effectively suppresses nitric oxide (NO) production and reduces the expression of iNOS, COX-2, and phosphorylated p38α and MK2 in response to lipopolysaccharide (LPS) stimulation. This compound demonstrates significant anti-inflammatory activity, making it valuable for research into inflammatory processes and potential therapeutic applications. -
FKBP12 Inhibitor
WAY-380153 is an FKBP12 inhibitor that demonstrates moderate binding affinity for FKBP12, with a KD of 19 μM measured via isothermal titration calorimetry and 15 μM via nuclear magnetic resonance. This compound is relevant for research applications involving neurotrophy and neuroprotection, serving as a valuable tool for investigating conditions related to neuronal health and function. -
FKBP51 Degrader, VHL Binder
SelDeg51 is a selective PROTAC degrader targeting FKBP51 with a Kd value of 18 nM and a maximum degradation efficacy (Dmax) of 90%. It facilitates the proteasomal degradation of FKBP51 through the formation of a ternary complex with FKBP51 and VHL, effectively reactivating glucocorticoid receptor signaling. SelDeg51 is particularly relevant for research in stress-related mental disorders, chronic pain, and obesity. -
Ligand for Target Protein for PROTAC
AP1867-3-(aminoethoxy) hydrochloride is a synthetic ligand targeting FKBP and plays a crucial role in the development of PROTAC-based therapies. This compound is utilized in the synthesis of PROTAC FKBP12 F36V degraders, facilitating targeted protein degradation. Its application extends to research in therapeutic modalities that employ ubiquitin-proteasome system for regulating protein levels in various diseases. -
FKBP Ligand
SLF is a synthetic ligand specifically targeting FK506-binding protein (FKBP), exhibiting an affinity of 3.1 μM for FKBP51 and an IC50 of 2.6 μM for FKBP12. This compound serves as a valuable tool in the development of PROTACs, enabling selective degradation of target proteins. Its application in chemical biology research facilitates the exploration of protein regulation and therapeutic strategies. -
FKBP12 Ligand
RapaBlock is a potent FKBP12 ligand that does not exert immunosuppressive effects and is characterized by its inability to penetrate the blood-brain barrier. This compound is primarily utilized in research to investigate FKBP12-related pathways and functions, offering valuable insights into cellular signaling mechanisms while minimizing unintended effects in neural tissue. -
FKBP12F36V PROTAC Degrader
dTAGV-1 is a selective proteolysis-targeting chimera (PROTAC) degrader designed to target FKBP12F36V-tagged proteins. This compound effectively induces the degradation of FKBP12F36V-Nluc in vivo, making it a valuable tool for studying protein turnover and function. Its application is particularly relevant in cellular and molecular biology research, facilitating the investigation of protein interactions and therapeutic targets. -
Ligand for Target Protein for PROTAC
AP1867-3-(aminoethoxy) is a synthetic ligand that targets FKBP, facilitating the design of PROTAC molecules. This compound is essential for the synthesis of the PROTAC FKBP12 F36V degrader, enabling targeted protein degradation in various biological contexts. Its use is crucial in research applications focused on protein regulation and therapeutic development. -
FKBP12 Inhibitor
ElteN378 is a selective inhibitor of FKBP12. This compound has demonstrated significant biological activity in the modulation of protein folding and signaling pathways. Research applications include investigations into neurodegenerative diseases such as Alzheimer's and Parkinson's, as well as studies on amyotrophic lateral sclerosis, proliferation disorders, and various cancer types.
